ArticleClinical advances in hematology & oncology : H&O2015
Adjuvant endocrine therapy in premenopausal women with breast cancer.
Article in Clinical advances in hematology & oncology : H&O, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.Cancer causes & control : CCC · 2025Pooled it
- Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Recent advances in hormone-based biopharmaceuticals for cancer therapy.Journal of the Egyptian National Cancer Institute · 2026Review
- The effects of tamoxifen and its metabolites on circulating estrogen metabolites among pre- and postmenopausal women.Steroids · 2026Article
- Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial.NPJ breast cancer · 2026Article
- Breast cancer radiotherapy and the risk of lung injury: Advances and perspectives.Advances in radiotherapy & nuclear medicine · 2026Article
- Article
- Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies.Journal of clinical medicine · 2024Review
- The effect of treatment and coping on the quality of life in breast cancer patients: a moderated mediation model.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Treatment and Survivorship Interventions to Prevent Poor Body Image Outcomes in Breast Cancer Survivors.Breast cancer (Dove Medical Press) · 2021Review
- Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.Journal of the Endocrine Society · 2018Review
- Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Drugs · 2017Review
- An update on the management of breast cancer in Africa.Infectious agents and cancer · 2017Review
- Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation.American journal of cancer research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer remains the leading cause of cancer-related mortality in premenopausal women. Multiple advances in local and systemic therapies have dramatically improved outcomes in women with hormone receptor-positive early-stage breast cancer. Despite these advances, early and late relapses occur. Therefore, multiple adjuvant endocrine therapy trials have been conducted with the goal of decreasing breast cancer recurrence and mortality. Recently, large international trials evaluating extended endocrine therapy and ovarian suppression with and without tamoxifen or exemestane have been reported. These studies add to the large body of existing data on adjuvant endocrine therapy in premenopausal women with breast cancer and provide additional therapeutic options in those at high risk of disease recurrence. This review will synthesize the most recent data and promote an evidence-based approach, highlighting quality-of-life concerns, to considering adjuvant endocrine therapies in premenopausal women.
Indexed as
Identifiers
27058571PMC4896158W2333480691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.